Avidity Partners 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 45 US equity positions worth $493.8m in its Q1 2026 13F filing. The largest position was DNTH at 35.8% of the reported book, followed by CGON and ORKA. Against the Q4 2025 filing, it opened 21 new positions, added to 11 and reduced 10 among the top 45 holdings.
What did Avidity Partners own in Q1 2026? Top 45 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2025 |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 35.8% | $176.6m | 2,104,184 | 0% | held |
| 2 | CGON CG ONCOLOGY INC | Healthcare | 17.7% | $87.2m | 1,288,948 | -12% | reduced |
| 3 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 7.6% | $37.3m | 760,424 | 15% | added |
| 4 | CATX PERSPECTIVE THERAPEUTICS INC | 5.1% | $25.2m | 6,049,999 | 88% | added | |
| 5 | JBIO JADE BIOSCIENCES INC | 4.0% | $19.7m | 1,400,708 | 0% | held | |
| 6 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 3.2% | $15.7m | 400,000 | 185% | added |
| 7 | TEVA TEVA PHARM ADR | Healthcare | 2.7% | $13.6m | 450,100 | 8% | added |
| 8 | CNTX CONTEXT THERAPEUTICS INC | 2.7% | $13.1m | 4,998,267 | -9% | reduced | |
| 9 | RGEN REPLIGEN CORP | Healthcare | 1.9% | $9.2m | 77,800 | 55% | added |
| 10 | PALVELLA THERAPEUTICS INC | 1.8% | $8.7m | 70,000 | 263% | added | |
| 11 | MDT MEDTRONIC INC | Healthcare | 1.8% | $8.7m | 100,000 | -7% | reduced |
| 12 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.7% | $8.5m | 950,000 | – | new |
| 13 | AKTS AKTIS ONCOLOGY INC | 1.7% | $8.4m | 468,566 | – | new | |
| 14 | IMUX IMMUNIC INC | Healthcare | 1.5% | $7.4m | 6,699,411 | 43% | added |
| 15 | DXCM DEXCOM | Healthcare | 1.1% | $5.7m | 90,000 | – | new |
| 16 | EHC ENCOMPASS HEALTH CORP | Healthcare | 0.8% | $4.1m | 42,000 | 33% | added |
| 17 | BSX BOSTON SCIENTIFIC CORPORATION | Healthcare | 0.8% | $3.8m | 60,000 | -48% | reduced |
| 18 | TENX TENAX THERAPEUTICS INC | 0.7% | $3.5m | 215,934 | – | new | |
| 19 | GILD GILEAD SCIENCES INC | Healthcare | 0.6% | $2.8m | 20,000 | – | new |
| 20 | PHAT PHATHOM PHARMACEUTICALS INC | 0.6% | $2.8m | 249,390 | 21% | added | |
| 21 | KPTI KARYOPHARM THERAPEUTICS INC | 0.5% | $2.6m | 463,741 | 245% | added | |
| 22 | CNC CENTENE CORP | Healthcare | 0.5% | $2.3m | 70,000 | -41% | reduced |
| 23 | MSLE SATELLOS BIOSCIENCE INC | 0.4% | $2.2m | 387,769 | – | new | |
| 24 | SCYX SCYNEXIS INC | 0.4% | $1.9m | 2,081,660 | 0% | held | |
| 25 | NTRA NATERA INC | Healthcare | 0.4% | $1.8m | 9,000 | -24% | reduced |
| 26 | ICLR ICON PLC | Healthcare | 0.4% | $1.8m | 16,000 | -52% | reduced |
| 27 | KVUE KENVUE INC ORD | Consumer Defensive | 0.3% | $1.7m | 100,000 | -57% | reduced |
| 28 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 0.3% | $1.7m | 115,000 | – | new |
| 29 | HIMS HIMS & HERS HEALTH INC | Healthcare | 0.3% | $1.6m | 75,000 | – | new |
| 30 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.3% | $1.5m | 15,000 | – | new |
| 31 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.3% | $1.4m | 30,000 | – | new |
| 32 | GMAB GENMAB A/S -SP ADR | Healthcare | 0.3% | $1.3m | 50,000 | -46% | reduced |
| 33 | CORT CORCEPT THERA | Healthcare | 0.2% | $1.2m | 30,000 | 36% | added |
| 34 | TEM TEMPUS AI INC | Healthcare | 0.2% | $1.1m | 25,000 | – | new |
| 35 | ABVX ABIVAX SA-ADR | 0.2% | $1.1m | 10,000 | – | new | |
| 36 | UNH UNITEDHEALTH GRP | Healthcare | 0.2% | $1.0m | 3,800 | – | new |
| 37 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.2% | $961.5k | 75,000 | – | new |
| 38 | ODD ODDITY TECH LTD-CL A | Consumer Defensive | 0.2% | $936.6k | 70,000 | – | new |
| 39 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 0.2% | $932.0k | 50,000 | – | new |
| 40 | PTON PELOTON INTERACTIVE INC-A | Consumer Cyclical | 0.2% | $858.0k | 200,000 | – | new |
| 41 | AVR ANTERIS TECHNOLOGIES GLOBAL | 0.2% | $832.5k | 150,000 | – | new | |
| 42 | ABUS ARBUTUS BIOPHARMA CORP | Healthcare | 0.1% | $562.5k | 125,000 | – | new |
| 43 | BRIDGEBIO ONCOLOGY THERAPEUTIC | 0.1% | $392.5k | 43,853 | – | new | |
| 44 | ACAD ACADIA PHARM | Healthcare | 0.1% | $288.6k | 12,967 | -88% | reduced |
| 45 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.0% | $79.5k | 6,660 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.